Greg Wolf to Aged, 80 and over
This is a "connection" page, showing publications Greg Wolf has written about Aged, 80 and over.
Connection Strength
0.417
-
Papagerakis S, Bellile E, Peterson LA, Pliakas M, Balaskas K, Selman S, Hanauer D, Taylor JM, Duffy S, Wolf G. Proton pump inhibitors and histamine 2 blockers are associated with improved overall survival in patients with head and neck squamous carcinoma. Cancer Prev Res (Phila). 2014 Dec; 7(12):1258-69.
Score: 0.059
-
Chepeha DB, Teknos TN, Fung K, Shargorodsky J, Sacco AG, Nussenbaum B, Jones L, Eisbruch A, Bradford CR, Prince ME, Moyer JS, Lee JS, Wolf GT. Lateral oromandibular defect: when is it appropriate to use a bridging reconstruction plate combined with a soft tissue revascularized flap? Head Neck. 2008 Jun; 30(6):709-17.
Score: 0.038
-
Eisbruch A, Marsh LH, Dawson LA, Bradford CR, Teknos TN, Chepeha DB, Worden FP, Urba S, Lin A, Schipper MJ, Wolf GT. Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys. 2004 May 01; 59(1):28-42.
Score: 0.028
-
Chen C, Lohavanichbutr P, Zhang Y, Houck JR, Upton MP, Abedi-Ardekani B, Agudo A, Ahrens W, Alemany L, Anantharaman D, Conway DI, Futran ND, Holcatova I, G?nther K, Hansen BT, Healy CM, Itani D, Kjaerheim K, Monroe MM, Thomson PJ, Witt BL, Nakoneshny S, Peterson LA, Schwartz SM, Zarins KR, Hashibe M, Brennan P, Rozek LS, Wolf G, Dort JC, Wang P. Prediction of survival of HPV16-negative, p16-negative oral cavity cancer patients using a 13-gene signature: A multicenter study using FFPE samples. Oral Oncol. 2020 01; 100:104487.
Score: 0.021
-
Zhang H, Kim S, Chen Z, Nannapaneni S, Chen AY, Moore CE, Sica G, Mosunjac M, Nguyen MLT, D'Souza G, Carey TE, Peterson LA, McHugh JB, Graham M, Komarck CM, Wolf GT, Walline HM, Bellile E, Riddell J, Pai SI, Sidransky D, Westra WH, William WN, Lee JJ, El-Naggar AK, Ferris RL, Seethala R, Grandis JR, Chen ZG, Saba NF, Shin DM. Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma. Head Neck. 2017 12; 39(12):2433-2443.
Score: 0.018
-
Gainor DL, Marchiano E, Bellile E, Spector ME, Taylor JMG, Wolf GT, Hogikyan ND, Prince ME, Bradford CR, Eisbruch A, Worden F, Shuman AG. Survival Outcomes in Patients with T2N0M0 (Stage II) Squamous Cell Carcinoma of the Larynx. Otolaryngol Head Neck Surg. 2017 10; 157(4):625-630.
Score: 0.018
-
Getz KR, Rozek LS, Peterson LA, Bellile EL, Taylor JMG, Wolf GT, Mondul AM. Family history of cancer and head and neck cancer survival. Laryngoscope. 2017 08; 127(8):1816-1820.
Score: 0.017
-
Prince V, Bellile EL, Sun Y, Wolf GT, Hoban CW, Shuman AG, Taylor JM. Individualized risk prediction of outcomes for oral cavity cancer patients. Oral Oncol. 2016 12; 63:66-73.
Score: 0.017
-
Choi SH, Terrell JE, Bradford CR, Ghanem T, Spector ME, Wolf GT, Lipkus IM, Duffy SA. Does Quitting Smoking Make a Difference Among Newly Diagnosed Head and Neck Cancer Patients? Nicotine Tob Res. 2016 12; 18(12):2216-2224.
Score: 0.017
-
Nguyen N, Bellile E, Thomas D, McHugh J, Rozek L, Virani S, Peterson L, Carey TE, Walline H, Moyer J, Spector M, Perim D, Prince M, McLean S, Bradford CR, Taylor JM, Wolf GT. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head Neck. 2016 07; 38(7):1074-84.
Score: 0.016
-
Arthur AE, Bellile EL, Rozek LS, Peterson KE, Ren J, Harris E, Mueller C, Jolly S, Peterson LA, Wolf GT, Djuric Z. Pretreatment serum xanthophyll concentrations as predictors of head and neck cancer recurrence and survival. Head Neck. 2016 04; 38 Suppl 1:E1591-7.
Score: 0.016
-
Virani S, Bellile E, Bradford CR, Carey TE, Chepeha DB, Colacino JA, Helman JI, McHugh JB, Peterson LA, Sartor MA, Taylor JM, Walline HM, Wolf GT, Rozek LS. NDN and CD1A are novel prognostic methylation markers in patients with head and neck squamous carcinomas. BMC Cancer. 2015 Oct 30; 15:825.
Score: 0.016
-
Gallagher KK, Sacco AG, Lee JS, Taylor R, Chanowski EJ, Bradford CR, Prince ME, Moyer JS, Wolf GT, Worden FP, Eisbruch A, Chepeha DB. Association Between Multimodality Neck Treatment and Work and Leisure Impairment: A Disease-Specific Measure to Assess Both Impairment and Rehabilitation After Neck Dissection. JAMA Otolaryngol Head Neck Surg. 2015 Oct; 141(10):888-93.
Score: 0.016
-
Stenmark MH, McHugh JB, Schipper M, Walline HM, Komarck C, Feng FY, Worden FP, Wolf GT, Chepeha DB, Prince ME, Bradford CR, Mukherji SK, Eisbruch A, Carey TE. Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis. Int J Radiat Oncol Biol Phys. 2014 Mar 01; 88(3):580-8.
Score: 0.014
-
Malhotra B, Moon J, Kucuk O, Clark JI, Urba SG, Wolf GT, Worden FP. Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329. Head Neck. 2014 Dec; 36(12):1712-7.
Score: 0.014
-
Dewyer NA, Wolf GT, Light E, Worden F, Urba S, Eisbruch A, Bradford CR, Chepeha DB, Prince ME, Moyer J, Taylor J. Circulating CD4-positive lymphocyte levels as predictor of response to induction chemotherapy in patients with advanced laryngeal cancer. Head Neck. 2014 Jan; 36(1):9-14.
Score: 0.013
-
Colacino JA, Dolinoy DC, Duffy SA, Sartor MA, Chepeha DB, Bradford CR, McHugh JB, Patel DA, Virani S, Walline HM, Bellile E, Terrell JE, Stoerker JA, Taylor JM, Carey TE, Wolf GT, Rozek LS. Comprehensive analysis of DNA methylation in head and neck squamous cell carcinoma indicates differences by survival and clinicopathologic characteristics. PLoS One. 2013; 8(1):e54742.
Score: 0.013
-
Duffy SA, Teknos T, Taylor JM, Fowler KE, Islam M, Wolf GT, McLean S, Ghanem TA, Terrell JE. Health behaviors predict higher interleukin-6 levels among patients newly diagnosed with head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2013 Mar; 22(3):374-81.
Score: 0.013
-
Arthur AE, Peterson KE, Rozek LS, Taylor JM, Light E, Chepeha DB, H?bert JR, Terrell JE, Wolf GT, Duffy SA. Pretreatment dietary patterns, weight status, and head and neck squamous cell carcinoma prognosis. Am J Clin Nutr. 2013 Feb; 97(2):360-8.
Score: 0.013
-
Duffy SA, Ronis DL, McLean S, Fowler KE, Gruber SB, Wolf GT, Terrell JE. Pretreatment health behaviors predict survival among patients with head and neck squamous cell carcinoma. J Clin Oncol. 2009 Apr 20; 27(12):1969-75.
Score: 0.010
-
Duffy SA, Khan MJ, Ronis DL, Fowler KE, Gruber SB, Wolf GT, Terrell JE. Health behaviors of head and neck cancer patients the first year after diagnosis. Head Neck. 2008 Jan; 30(1):93-102.
Score: 0.009
-
Cheng SS, Terrell JE, Bradford CR, Ronis DL, Fowler KE, Prince ME, Teknos TN, Wolf GT, Duffy SA. Variables associated with feeding tube placement in head and neck cancer. Arch Otolaryngol Head Neck Surg. 2006 Jun; 132(6):655-61.
Score: 0.008
-
Feng M, Jabbari S, Lin A, Bradford CR, Chepeha DB, Teknos TN, Worden FP, Tsien C, Schipper MJ, Wolf GT, Dawson LA, Eisbruch A. Predictive factors of local-regional recurrences following parotid sparing intensity modulated or 3D conformal radiotherapy for head and neck cancer. Radiother Oncol. 2005 Oct; 77(1):32-8.
Score: 0.008
-
Terrell JE, Ronis DL, Fowler KE, Bradford CR, Chepeha DB, Prince ME, Teknos TN, Wolf GT, Duffy SA. Clinical predictors of quality of life in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2004 Apr; 130(4):401-8.
Score: 0.007